Sites of failure and times to failure in carcinoma of the vulva treated conservatively

A Gynecologic Oncology Group study

Frederick Stehman, B. N. Bundy, H. Ball, D. L. Clarke-Pearson, L. D. Lagasse

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

OBJECTIVE: The objective of this review was to examine the patterns of failure after conservative therapy for vulvar carcinoma to establish a basis for the design of prospective cooperative trials in this disease. STUDY DESIGN: The records and characteristics of all patients in whom cancer recurred after conservative therapy in two prospective clinical trials were analyzed. RESULTS: Of 143 patients who received one or more modifications of therapy, 37 patients had recurrence of cancer and 20 died of the disease. The median intervals to recurrence were 35.9 months for vulvar cancer and 7.0 months for groin cancer (p = 0.0002). There were 12 groin recurrences; 11 (91.7%) of these patients have died of the disease. The median survival time after recurrence was 52.4 months for patients with vulvar cancer and 9.4 months for those with groin cancer (p = 0.0025). CONCLUSIONS: Groin cancer recurs earlier than vulvar cancer among patients treated conservatively. Future trials that evaluate modified therapy to the groin need to include early interim analyses. Follow-up for >36 months after study entry may not be necessary to evaluate the impact of new treatments.

Original languageEnglish (US)
Pages (from-to)1128-1133
Number of pages6
JournalAmerican Journal of Obstetrics and Gynecology
Volume174
Issue number4
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Vulva
Groin
Vulvar Neoplasms
Carcinoma
Recurrence
Neoplasms
Therapeutics
Clinical Trials
Survival

Keywords

  • patterns of failure
  • recurrent cancer
  • Vulvar cancer

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Sites of failure and times to failure in carcinoma of the vulva treated conservatively : A Gynecologic Oncology Group study. / Stehman, Frederick; Bundy, B. N.; Ball, H.; Clarke-Pearson, D. L.; Lagasse, L. D.

In: American Journal of Obstetrics and Gynecology, Vol. 174, No. 4, 1996, p. 1128-1133.

Research output: Contribution to journalArticle

@article{b220a5f46e5542238201baa88a600b51,
title = "Sites of failure and times to failure in carcinoma of the vulva treated conservatively: A Gynecologic Oncology Group study",
abstract = "OBJECTIVE: The objective of this review was to examine the patterns of failure after conservative therapy for vulvar carcinoma to establish a basis for the design of prospective cooperative trials in this disease. STUDY DESIGN: The records and characteristics of all patients in whom cancer recurred after conservative therapy in two prospective clinical trials were analyzed. RESULTS: Of 143 patients who received one or more modifications of therapy, 37 patients had recurrence of cancer and 20 died of the disease. The median intervals to recurrence were 35.9 months for vulvar cancer and 7.0 months for groin cancer (p = 0.0002). There were 12 groin recurrences; 11 (91.7{\%}) of these patients have died of the disease. The median survival time after recurrence was 52.4 months for patients with vulvar cancer and 9.4 months for those with groin cancer (p = 0.0025). CONCLUSIONS: Groin cancer recurs earlier than vulvar cancer among patients treated conservatively. Future trials that evaluate modified therapy to the groin need to include early interim analyses. Follow-up for >36 months after study entry may not be necessary to evaluate the impact of new treatments.",
keywords = "patterns of failure, recurrent cancer, Vulvar cancer",
author = "Frederick Stehman and Bundy, {B. N.} and H. Ball and Clarke-Pearson, {D. L.} and Lagasse, {L. D.}",
year = "1996",
doi = "10.1016/S0002-9378(96)70654-3",
language = "English (US)",
volume = "174",
pages = "1128--1133",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Sites of failure and times to failure in carcinoma of the vulva treated conservatively

T2 - A Gynecologic Oncology Group study

AU - Stehman, Frederick

AU - Bundy, B. N.

AU - Ball, H.

AU - Clarke-Pearson, D. L.

AU - Lagasse, L. D.

PY - 1996

Y1 - 1996

N2 - OBJECTIVE: The objective of this review was to examine the patterns of failure after conservative therapy for vulvar carcinoma to establish a basis for the design of prospective cooperative trials in this disease. STUDY DESIGN: The records and characteristics of all patients in whom cancer recurred after conservative therapy in two prospective clinical trials were analyzed. RESULTS: Of 143 patients who received one or more modifications of therapy, 37 patients had recurrence of cancer and 20 died of the disease. The median intervals to recurrence were 35.9 months for vulvar cancer and 7.0 months for groin cancer (p = 0.0002). There were 12 groin recurrences; 11 (91.7%) of these patients have died of the disease. The median survival time after recurrence was 52.4 months for patients with vulvar cancer and 9.4 months for those with groin cancer (p = 0.0025). CONCLUSIONS: Groin cancer recurs earlier than vulvar cancer among patients treated conservatively. Future trials that evaluate modified therapy to the groin need to include early interim analyses. Follow-up for >36 months after study entry may not be necessary to evaluate the impact of new treatments.

AB - OBJECTIVE: The objective of this review was to examine the patterns of failure after conservative therapy for vulvar carcinoma to establish a basis for the design of prospective cooperative trials in this disease. STUDY DESIGN: The records and characteristics of all patients in whom cancer recurred after conservative therapy in two prospective clinical trials were analyzed. RESULTS: Of 143 patients who received one or more modifications of therapy, 37 patients had recurrence of cancer and 20 died of the disease. The median intervals to recurrence were 35.9 months for vulvar cancer and 7.0 months for groin cancer (p = 0.0002). There were 12 groin recurrences; 11 (91.7%) of these patients have died of the disease. The median survival time after recurrence was 52.4 months for patients with vulvar cancer and 9.4 months for those with groin cancer (p = 0.0025). CONCLUSIONS: Groin cancer recurs earlier than vulvar cancer among patients treated conservatively. Future trials that evaluate modified therapy to the groin need to include early interim analyses. Follow-up for >36 months after study entry may not be necessary to evaluate the impact of new treatments.

KW - patterns of failure

KW - recurrent cancer

KW - Vulvar cancer

UR - http://www.scopus.com/inward/record.url?scp=0029875853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029875853&partnerID=8YFLogxK

U2 - 10.1016/S0002-9378(96)70654-3

DO - 10.1016/S0002-9378(96)70654-3

M3 - Article

VL - 174

SP - 1128

EP - 1133

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 4

ER -